{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:21Z","timestamp":1792079121743,"version":"4.4.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi261061-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) is a targeted radioligand therapy approved for patients with metastatic androgen pathway modulator\u2013resistant (mAPMR) prostate cancer after progression on androgen receptor pathway inhibitors (ARPIs). Data to guide treatment sequencing are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261061-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate survival outcomes in patients with mAPMR prostate cancer receiving Lu-177 PSMA by line of therapy and the timing of taxane exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261061-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study used a deidentified electronic health record research database to obtain comprehensive longitudinal oncology data from community and academic practices across the US. Among patients with metastatic prostate cancer in the dataset, those who received Lu-177 PSMA after an ARPI between December 19, 2018, and June 23, 2025, met the inclusion criteria. The data cutoff was June 30, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261061-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Receipt of Lu-177 PSMA, stratified by line of therapy and timing of taxane exposure (before Lu-177 PSMA, after Lu-177 PSMA, or never received taxane).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261061-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Primary end points were clinical time to next treatment (TTNT; defined as the time from Lu-177 PSMA initiation to next systemic therapy or death) and clinical overall survival (OS; defined as the time from Lu-177 PSMA initiation to death). Both outcomes were censored at last follow-up and estimated using the Kaplan-Meier method with 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261061-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 850 patients included, the median (IQR) age was 74 (68-80) years; most were treated in community settings (598 [70.4%]) and had commercial insurance (520 [61.2%]). A total of 466 patients (54.8%) received taxane before Lu-177 PSMA, 35 (4.1%) received taxane after Lu-177 PSMA, and 349 (41.1%) never received taxane. Median clinical TTNT and clinical OS with Lu-177 PSMA were 8.0 (95% CI, 7.4-9.0) months and 12.0 (95% CI, 11.0-13.0) months for patients with taxane exposure before Lu-177 PSMA; 10.0 (95% CI, 9.2-11.0) months and 14.0 (95% CI, 13.0-17.0) months for patients who never received taxane; and 6.0 (95% CI, 4.9-8.0) months and 16.0 (95% CI, 13.0\u2013not reached) months for patients with taxane exposure after Lu-177 PSMA, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261061-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cohort study, outcomes with Lu-177 PSMA were broadly consistent across treatment lines and taxane sequencing groups. These findings may help inform patient counseling, although prospective studies are needed to determine the optimal treatment sequencing strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.39276","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:31Z","timestamp":1792076431000},"page":"e2639276","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Varun","family":"Nandakumar","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjung","family":"Jo","sequence":"additional","affiliation":[{"name":"Cancer Biostatistics, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Gebrael","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Irem","family":"Ozay","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnam","family":"Goel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Revillo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejita","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sayegh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Mathew Thomas","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"4","key":"zoi261061r1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/biomedicines9040430","article-title":"177Lu-PSMA therapy in metastatic castration-resistant prostate cancer.","volume":"9","author":"Sanli","year":"2021","journal-title":"Biomedicines"},{"issue":"12","key":"zoi261061r2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi261061r3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10459","key":"zoi261061r4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"zoi261061r5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN Clinical Practice Guidelines in oncology.","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"9596","key":"zoi261061r7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"zoi261061r9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study).","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"zoi261061r10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-021-00801-w","article-title":"Real-world data analysis of efficacy and survival after lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer.","volume":"16","author":"Meyrick","year":"2021","journal-title":"Target Oncol"},{"issue":"3","key":"zoi261061r11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","article-title":"Real-world outcomes and predictive biomarkers for 177lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant prostate cancer: a European Association of Urology Young Academic Urologists Prostate Cancer Working Group multi-institutional observational study.","volume":"7","author":"Kafka","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"zoi261061r13","doi-asserted-by":"publisher","first-page":"S1630","DOI":"10.1016\/j.annonc.2025.09.105","article-title":"LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21.","volume":"36(Suppl 2)","author":"Chi","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi261061r14","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10276","key":"zoi261061r15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"zoi261061r16","author":"Nault"},{"key":"zoi261061r6","unstructured":"Database characterization guide. Flatiron.com. Accessed March 22, 2026. https:\/\/flatiron.com\/database-characterization"},{"key":"zoi261061r8","unstructured":"R: The R Project for Statistical Computing. Accessed March 20, 2026. https:\/\/www.r-project.org\/"},{"key":"zoi261061r12","unstructured":"177 LuPSMA-617 vs docetaxel in metastatic castration resistant and PSMA-positive prostate cancer. ClinicalTrials.gov identifier: NCT04663997. Updated March 27, 2026. Accessed September 3, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04663997"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855350\/nandakumar_2026_oi_261061_1791405257.6122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:33Z","timestamp":1792076433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.39276","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}